
    
      Carboplatin and pemetrexed are FDA approved chemotherapy agents for patients with advanced
      non squamous non small cell lung cancer. Bevacizumab is also FDA approved in lung cancer ,
      and the combination of all three drugs is promising. The doctors directing this research want
      to learn how to better personalize drug dosing of bevacizumab by identifying people who could
      safely take a higher dose of the drug.
    
  